WeSearch

If a Lyme disease vaccine gets approved, how would it go over? We asked hunters

·6 min read · 0 reactions · 0 comments · 35 views
TL;DR · WeSearch summary

Health If a Lyme disease vaccine gets approved, how would it go over? We asked hunters June 27, 20266:30 AM ET From By Bram Sable-Smith Matthew Mealer holds up his targets at the Busch Shooting Range in Weldon Spring, Missouri, in May. Mealer said he's generally skeptical of new vaccines but might consider one for Lyme disease if it proves safe and effective.

Key facts
About this source

NPR — News files mainly under news. We currently carry 541 of its stories.

Original article
NPR Topics: News
Read full at NPR Topics: News →

Story provenance

Source · retrieval · rights · ranking — open for full record
inspect →

Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.

Record

Original publisherNPR Topics: News
Canonical URLhttps://www.npr.org/2026/06/27/nx-s1-5859907/lyme-disease-vaccine-hesitancy-rural-hunters
Publication timeSat, 27 Jun 2026 06:30:00 -0400
Retrieval time2026-06-27T11:01:16.323Z
Last seen2026-06-27T11:01:16.323Z
Headline sourcePublisher (no WeSearch rewrite)
Excerpt sourcepublisher body
Excerpt methodFirst ~120 words (~800 chars) of extracted publisher body, fair-use limited.
SummaryWeSearch · cerebras-chat (WeSearch summarizer)
Summary source textcontentText
Citation coverageSummary is a WeSearch-generated derivative; primary citation is the original publisher URL.
ClustergwC-M8c5PFag
Cluster logicGrouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison.
Ranking reasonStory pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking.
Publisher visitYes — open original
Substitutes article?No — link-out required for full text

Rights status (four layers)

Publisher-declared
No publisher-confirmed rights record for this source yet.
Machine-readable
No source-specific machine-readable restriction detected beyond the public feed.
WeSearch interpretation
WeSearch declared handling (basis: Derived from the published RSS/Atom feed). This is WeSearch policy, not a legal grant on the publisher's behalf.
Unknown
Retrieval and training permissions are not asserted unless the publisher confirms them.

WeSearch handling by dimension

Indexing May the item be indexed (stored, ranked, made findable)? Allowed
Snippet May a short excerpt of the publisher's text be shown? Allowed
AI summary May WeSearch generate its own short summary of the article? Limited
Retrieval / RAG May the content be exposed for third-party retrieval-augmented generation? Not asserted
Model training May the content be used to train AI models? Not asserted
Commercial reuse May the content be reused commercially? Not permitted

Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.

Opening excerpt (first ~120 words) tap to expand

Health If a Lyme disease vaccine gets approved, how would it go over? We asked hunters June 27, 20266:30 AM ET From By Bram Sable-Smith Matthew Mealer holds up his targets at the Busch Shooting Range in Weldon Spring, Missouri, in May. Mealer said he's generally skeptical of new vaccines but might consider one for Lyme disease if it proves safe and effective. Kyle Pyatt for KFF Health News hide caption toggle caption Kyle Pyatt for KFF Health News It's tick season, possibly the worst in a decade. More and more Americans are being exposed to these parasites as climate change expands the range where they can survive.

Excerpt limited to ~120 words for fair-use compliance. The full article is at NPR Topics: News.

Anonymous · no account needed
Share 𝕏 Facebook Reddit LinkedIn Threads WhatsApp Bluesky Mastodon Email

Discussion

0 comments

More from NPR Topics: News